PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1354722
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1354722
The global cell & gene therapy bioanalytical testing services market is poised for remarkable growth, with a projected CAGR of 8% during the period from 2023 to 2030. By the end of 2030, the market size is expected to reach an estimated US$0.8 billion, according to a comprehensive market analysis.
Cell and gene therapy bioanalytical testing services encompass specialized laboratory services dedicated to the analysis of cellular and genetic components in therapeutic products. These therapies represent cutting-edge medical treatments that involve the modification or manipulation of a patient's genes or cells to treat or prevent various diseases. Bioanalytical testing services play a critical role in ensuring the safety, efficacy, and quality of these therapies by conducting a wide range of tests and analyses on therapeutic products.
As the field of cell and gene therapies continues to advance, with innovative treatments being developed for conditions such as genetic disorders, cancer, and autoimmune diseases, the demand for comprehensive bioanalytical testing services is on the rise. Regulatory agencies like the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) impose stringent requirements regarding the quality, safety, and efficacy of cell and gene therapies. Bioanalytical testing services are indispensable in meeting these regulatory standards and obtaining the necessary approvals.
The market for cell & gene therapy bioanalytical testing services is expected to witness significant growth:
Driving Factors
Growth Opportunities Across Regions
Leading players in the cell & gene therapy bioanalytical testing services market include: BioAgilytix Labs, KCAS Bioanalytical Services, Laboratory Corporation of America Holdings, Pharmaceutical Product Development, Inc., Prolytix, Pharmaron, Charles River Laboratories, Syneos Health, SGS SA, and CD BioSciences.